Navigation Links
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
Date:12/1/2008

ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America. These trials are conducted in collaboration with The National Institutes of Health (NIH), and the HIV Vaccine Trials Network (HVTN).

"It is of significant importance to report this major development on this very day in which the world commemorates WORLD AIDS DAY. Despite setbacks reported recently with other vaccine trials, our vaccine is progressing and paving the way for a solution that would potentially make this commemorative day more joyful," commented Dr. Robert McNally, GeoVax's President and CEO.

Dr. Harriet Robinson, Vice President of Research and Development of GeoVax Labs, Inc., stated, "We feel privileged to be in the position to launch our Phase 2a human trial. Going forward, each clinical site's review board will start the vaccination process, when deemed appropriate and ready. Accordingly, HVTN's pharmacy will release the vaccines to each designated institution as directed by each site's local review board."

Trial site arrangements and other details of the study were confirmed in a recent meeting held in Seattle, Washington, between the HVTN and GeoVax's scientific personnel. The Phase 2a human clinical trial will involve 150 vaccinees and 75 placebo (control) participants. The vaccine regimen employs a two-component "prime-boost strategy." Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which "primes" the immune system followed by the second vaccine, GeoVax's HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National Necrotizing ... Fernando Davila has been successfully treated for a life ... Dr, Anibal R. Gauto , Medical Director of Inpatient ... Eisenhower Medical Center in Rancho Mirage, California ... pioneered by Dr. John Crew at Seton Hospital ...
(Date:8/20/2014)... 2014 Research and Markets  has announced the ... report to their offering. Global Market Report ... Pralmorelin globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... a mastectomy has long been an option, but a new ... it. "The most common reasons women didn,t undergo reconstruction ... in more surgery or they were focused on their cancer ... surgery at Memorial Sloan Kettering Cancer Center, in New York ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... cause of endophthalmitis, a potentially blinding condition that can ... are the well-known staphylococci ("staph") and ... published in the August issue of Ophthalmology ... cases at New York Eye and Ear Infirmary of ... that gram-positive bacteria, which include staph and strep infections, ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... in the search for new Alzheimer,s,drugs, BIRMINGHAM, ... not-for-profit organization that conducts basic and applied,research in ... development --,today announced it has received funding from ... small molecules that activate Nuclear,Factor-kB (NF-kB)--a transcription factor ...
... -, NEW YORK, Oct. 1 American Media, Inc. (AMI) ... Form 10-Q,for the quarterly period ended June 30, 2007. In the ... first quarter of fiscal 2007 were $121.8 million, as ... 2006, representing a 5.6% increase., ...
... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
... 1. Organizations Issue Comprehensive Guidelines for Treating Low Back Pain ... , (Clinical Guidelines, p. 487.) (NOTE: This article is ... A separate news release will be issued.) , ... at Suppressing Hepatitis B Virus , A 52-week, randomized ...
... Flextronics International,Ltd. (Nasdaq: FLEX ) announced ... Corporation (NYSE: SLR ) creating the most ... vertically integrated,electronics manufacturing services ("EMS"). As a ... worldwide,EMS capabilities, from design resources to end-to-end vertically ...
... has named Glenn Adriance as Vice President of ... proven track record of developing, implementing,and managing effective ... "Glenn brings a wealth of experience to ... am pleased to welcome Glenn to the Mesa ...
Cached Medicine News:Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:American Media Operations, Inc. Files Form 10-Q For First Quarter 2007 2Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:Annals of Internal Medicine tip sheet for Oct. 2 2Health News:Flextronics Completes Acquisition of Solectron 2Health News:Flextronics Completes Acquisition of Solectron 3Health News:Flextronics Completes Acquisition of Solectron 4Health News:Flextronics Completes Acquisition of Solectron 5
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical micro...
The DEI 750 MD from Optronics is a surgical 3 CCD color microscope camera with a 10 meter head cable. Easily mounts on your microscopes C-mount adapter and is the best choice for your surgical imagin...
Medicine Products: